Skip to main content
. 2023 Nov 20;30(11):10033–10042. doi: 10.3390/curroncol30110729

Table 1.

Approval scenario of ALK TKIs in the US, Europe, and Italy *.

FDA EMA AIFA
Crizotinib 2011 2012 a
2015 b
2015 a
2017 b
Ceritinib 2014 c
2017 b
2015 c
2017 b
2017 c
2019 b
Alectinib 2016 c
2017 b
2017 c
2017 b
2018 c
2018 b
Brigatinib 2017 c
2020 b
2018 c
2020 b
2020 c
2020 b
Lorlatinib 2018 d
2021 b
2019 d
2021 b
2021 d

a Previously treated with chemotherapy. b Front-line. c Post-crizotinib. d Post-ALK TKI. * Updated approvals by July 2023.